These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3191938)

  • 21. Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil.
    Eichelbaum M; Somogyi A
    Eur J Clin Pharmacol; 1984; 26(1):47-53. PubMed ID: 6714292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indoramin as second step therapy in the management of benign essential hypertension.
    Montenero AS; Mazzari M; Schiavoni G; Manzoli U; Gherardi S
    Pharmatherapeutica; 1983; 3(6):417-21. PubMed ID: 6353433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential blockade of alpha-adrenoceptors by indoramin.
    Nicholls DP; O'Connor PC; Harron DW; Leahey WJ; Shanks RG
    Br J Clin Pharmacol; 1984 Jun; 17(6):719-28. PubMed ID: 6146328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of therapeutic concentrations of indoramin by liquid chromatography with fluorimetric detection.
    Swaisland AJ
    Analyst; 1981 Jun; 106(1263):717-9. PubMed ID: 7258656
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers.
    Cullberg M; Arfvidsson C; Larsson B; Malmgren A; Mitchell P; Wählby Hamrén U; Wray H
    Drugs R D; 2018 Jun; 18(2):149-159. PubMed ID: 29856004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indoramin as an antihypertensive agent in the treatment of essential hypertension. A multicentre trial.
    Bednarek MR; Schoeman HS
    S Afr Med J; 1983 Mar; 63(11):398-400. PubMed ID: 6338603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel.
    Yousef AM; Arafat T; Bulatova NR; Al-Zumyli R
    J Clin Pharm Ther; 2008 Aug; 33(4):439-49. PubMed ID: 18613862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin.
    Pierce V; Shepperson NB; Todd MH; Waterfall JF
    Br J Pharmacol; 1986 Feb; 87(2):433-41. PubMed ID: 3955309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation.
    Kovarik JM; Mueller EA; van Bree JB; Tetzloff W; Kutz K
    J Pharm Sci; 1994 Mar; 83(3):444-6. PubMed ID: 8207699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.
    Golabchifar AA; Rezaee S; Dinan NM; Kebriaeezadeh A; Rouini MR
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):527-39. PubMed ID: 26189007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indoramin in the treatment of hypertension. A mini-review and update.
    Archibald JL; Turner P
    S Afr Med J; 1983 Feb; 63(9):307-9. PubMed ID: 6338605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variability of beta-blocker pharmacokinetics in young volunteers.
    Jack DB; Quarterman CP; Zaman R; Kendall MJ
    Eur J Clin Pharmacol; 1982; 23(1):37-42. PubMed ID: 6127220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers.
    van Marle S; van Vliet A; Sollie F; Kambayashi Y; Yamada-Sawada T
    Int J Clin Pharmacol Ther; 2005 Jun; 43(6):282-93. PubMed ID: 15968885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.
    Nicholls DP; McNeill J; O'Connor PC; Harron DW; Leahey WJ; Shanks RG
    Br J Clin Pharmacol; 1984 Aug; 18(2):215-21. PubMed ID: 6386022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trandolapril: pharmacokinetics of single oral doses in healthy male volunteers.
    Lenfant B; Mouren M; Bryce T; De Lauture D; Strauch G
    J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S38-43. PubMed ID: 7527100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study.
    Morain P; Robin JL; De Nanteuil G; Jochemsen R; Heidet V; Guez D
    Br J Clin Pharmacol; 2000 Oct; 50(4):350-9. PubMed ID: 11012558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular effects of indoramin in man--a dose ranging study.
    Nicholls DP; Harron DW; Shanks RG
    Br J Clin Pharmacol; 1983 Jan; 15(1):31-6. PubMed ID: 6849741
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.